Vertex Pharmaceuticals Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $236.1M | $179.5M | $56.6M | $240.6M |
| FY2017 | $844.9M | $745.5M | $99.4M | $293.2M |
| FY2018 | $1.27B | $1.17B | $95.4M | $325.0M |
| FY2019 | $1.57B | $1.49B | $75.4M | $360.5M |
| FY2020 | $3.25B | $2.99B | $259.8M | $429.5M |
| FY2021 | $2.64B | $2.41B | $235.0M | $441.4M |
| FY2022 | $4.13B | $3.93B | $204.7M | $491.3M |
| FY2023 | $3.54B | $3.34B | $200.4M | $581.2M |
| FY2024 | $-492.6M | $-790.3M | $297.7M | $698.5M |
| FY2025 | $3.63B | $3.19B | $437.6M | $685.9M |